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ABSTRACT  
1,2,3-Benzotriazole (BTA) is a heterocyclic compound with three nitrogen atoms. It is a polar and colourless compound which can be used for 
its great versatility. The enormous investigations on derivatives of benzotriazole reveal wide applicability for tagging and delivering a number 
of heterocyclic nuclei with this molecule. In the present work synthesis of several derivatives of 1-(substituted)-5-[(N-benzotriazolomethyl)-
1,3, 4-thiadiazolyl]- imidazole-2-thione has been synthesized and are evaluated for their anxiolytic activity. The antianxiety activities of the 
synthesized derivatives were evaluated using EPM test and Bright and dark box test experimental models of anxiety. All results were expressed 
as mean± standard error mean (SEM) and analysed by one-way ANOVA. Post-hoc comparisons were performed by applying Dunnet’s test. P 
<0.05 was considered statistically significant.  
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INTRODUCTION:  
1,2,3-benzotriazoles were reported to have potential 
fungicidal [1] and antibacterial activity [2]. Similarly 1,3,4-
thiadiazole derivatives were also reported to possess 
fungicidal, herbicidal, bactericidal [3], pesticidal, insecticidal, 
antihistaminic, antiamoebic [4], CNS depressant, 
antihypertensive, anticonvulsant, hypnotic, analgesic [5], 
anti-inflammatory [6] and agonist for 5-Ht receptor [7]. 4-
thiazolidinone nucleus has also occupied a unique place in 
the field of medicinal chemistry due to its wide range of 
biological activities like antibacterial, anticancer [8], 
Respiratory, syncytial, virus Inhibitor [9], anticonvulsant 
[10], sciatic nerve blocking, local anaesthetic, inhibitors of 
human (CK2) protein kinase [11], hypnotic, fungicidal, 
cysticidal, anti-leukemic and antioxidant activity. In view of 
potential biological activities of benzotriazole, thiadiazole 
and imidazole an attempt has made to unite these nuclei 
together and synthesize some new derivatives of 
benzotriazole (X1-X6) to screen out some derivatives for 
significant anxiolytic activity. The procedure of synthesis has 
been outlined in Scheme 1. Anxiety is a normal emotional 
response which when chronic or severe becomes 
pathological and can aggravate cardiovascular and 
psychiatric disorders [12]. Despite the development of new 
molecules for pharmacotherapy of anxiety, the treatment is 
challenging as they produce various side effects or exhibit 
tolerance on continuous use.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1: Synthesis of 1-(substituted)-5-[(N-
benzotriazolomethyl)-1,3, 4-thiadiazolyl]- imidazole-2-
thione derivatives
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MATERIALS AND METHODS  
The chemicals and reagents used in this were of AR and LR 
grade. They were procured from CDH, Hi-Media, Merck, 
Sigma Aldrich and Ranbaxy. The melting points of the 
synthesized compounds were determined by using Thiel’s 
melting point apparatus (open capillary tube method) and 
all the compounds gave sharp melting points and are 
uncorrected. Purity of the compounds was ascertained by 
thin layer chromatography using silica gel-G as stationary 
phase and appropriate mixtures of the following solvents as 
mobile phase: n-butanol, glacial acetic acid and water. The 
spots resolved were visualized using iodine chamber. The IR 
spectra of the synthesized compounds were recorded on a 
Fourier Transform IR spectrophotometer (Perkin Elimer BX-
II) in the range of 400-4000 using diffuse reflectance system 
and values of peaks (ʋ) are reported in cm-1. 1H NMR 
spectra were recorded on Bruker Av- II 400 MHz NMR 
spectrometer and chemical shifts (δ) are reported in ppm 
downfield from internal reference Tetramethylsilane (TMS). 
Mass spectra were recorded on Shimadzu LC-MS model 
2010A. Elemental analysis of the newly synthesized 
compounds was carried out using Euro - E 3000 series 
elemental analyzer. 1-(substituted)-5-[(N-benzotriazolo 
methyl) -1,3,4-thiadiazolyl]-imidazole-2- thione were 
prepared as per the method described in the literature [13-
15]. The Synthetic Procedure involved the following six 
steps as stated below. 
Experimental Section: 
Ethyl N1-benzotriazoloacetate, 1 
A mixture of benzotriazole (0.1 mole), ethyl chloroacetate 
(0.1 mole) and K2CO3 (3 gm) in acetone (60 ml) was stirred 
for 8 hrs. The solvent was then removed under reduced 
pressure and the solid mass obtained are subjected to 
extraction with petroleum ether. The solvent was removed 
under reduced pressure to yield needle shaped brown 
crystals of compound 1; yield 90%, m.p. 39-400C. Elemental 
analysis: Found C, 58.6%; H, 5.4%; N, 20.4% Calc. for 
C10H11N3O2; C, 58.5%; H, 5.4%; N, 20.5%; IR: 1740 (C=O); 
1232, 1462 (N-CH2); 1HNMR (D2O): 3.75 (s, 2H, N-CH2), 4.25 
(q, 2H, COOCH2), 1.30 (t, 3H, CH3) and 6.90-7.91 (m, 4H, 
ArH); MS: m/z 205 (M+). 
1-( N1-benzotriazoloacetyl)-thiosemicarbazide, 2 
Compound 1 (0.07 mole) and thiosemicarbazide (0.07 mole) 
in ethanol (50 ml) was stirred for 5 hrs and then refluxed on 
steam bath for 2 hrs. The excess of solvent was removed 
under reduced pressure and recrystallised from chloroform-
hexane (2:1 v/v) to yield pale yellow crystals of product 2; 
yield 86%, m.p. 103-1040C. Elemental analysis: Found C, 
43.3%; H, 4.1%; N, 33.5% Calc. for C9H10N6OS; C, 43.2%; H, 
4.1%; N, 33.6%; IR: 3340 (-NH2); 1670 (-CONH-); 1130 
(C=S); 1HNMR (CDCl3): 3.80 (s, 2H, N-CH2), 8.30 (m, 4H, NH-
NH-CS-NH2), and 6.45-7.21 (m, 4H, ArH); MS: m/z 250 (M+) 
2-amino-5-(N1- benzotriazolomethyl)- 1,3,4 – 
thiadiazole, 3 
The thiosemicarbazide 2 (0.05 mole) together with conc. 
H2SO4 (10 ml) was kept overnight at room temperature, 
neutralized with ammonia and extracted with ether. The 
ether was distilled off and the product so obtained was 
crystallised from 80% ethanol to get yellowish leaflet of 
compound 3; yield 85%, m.p. 120-1210C (d). Elemental 
analysis: Found C, 46.5%; H, 3.4%; N, 36.0% Calc. for 
C9H8N6S; C, 46.6%; H, 3.4%; N, 36.1%; IR: 3350 (-NH2); 1600 
(-C=N-); 690 (C-S-C); 1HNMR (CDCl3): 3.80 (s, 2H, N-CH2), 
4.40 (s, 2H, -NH2), and 6.95-7.81 (m, 4H, ArH); MS: m/z 232 
(M+) 
1-(5-((1H-benzo[d][1,2,3]triazole-1-yl)methyl)-1,3,4-
thiadiazole-2-yl)-3-ethyl thiourea, 4 
Compound 3 (20 mmole) and ethyl isothiocyanate (20 
mmole) in dioxane (5 ml) was heated under reflux for 6 hrs, 
concentrated and the residue was recrystallised from 
dioxane to give 4; yield 84%, m.p. 123-1240C. Elemental 
analysis: Found C, 45.10%; H, 4.1%; N, 30.73% Calc. for 
C12H13N7S2; C, 45.13%; H, 4.10%; N, 30.70%; IR: 3210, 3300 
(-NH-); 1610 (-C=N-); 1300 (C=S); 1HNMR (CDCl3): 4.90 (s, 
2H, N-CH2), 8.4, 8.2 (2s, 2H, 2NH), 7.25-8.0 (m, 4H, ArH), 
4.43 (q, 2H, -CH2-) and 1.29 (t, 3H, -CH3); MS: m/z 319 (M+) 
3-(-5-((1H-benzo[d][1,2,3]triazole-1-yl)methyl)-1,3,4-
thiadiazole-2-yl)-1-ethyl -4-phenyl-1,3-dihydro -2H-
imidazole-2-thione, 5 (a) / X1 . 
To a stirred solution of compound 4 (10 mmole) and 
phenacyl bromide, in glacial acetic acid (50ml) was heated 
under reflux for 12 hrs. The obtained solid was 
recrystallised from acetic acid to give 5 (a); yield 72%, m.p. 
130-1310C. Elemental analysis: Found C, 57.21%; H, 4.0%; N, 
23.33% Calc. for C20H17N7S2; C, 57.26%; H, 4.0%; N, 23.37%; 
IR: 3100 (CH-Ar); 2930 (CH-aliphatic); 1320 (C=S); 1HNMR 
(CDCl3): 4.90 (s, 2H, N-CH2), 6.8 (s, 1H, =CH), 7.36-8.0 (m, 9H, 
ArH), 4.21 (q, 2H, -CH2-) and 1.26 (t, 3H, -CH3); MS: m/z 419 
(M+) 
Other compounds 5(b-f) were synthesized similarly using 
various isothiocyanate in place of ethyl isothiocyanate. 
Characterization data are present in table 1. 
Determination of Anxiolytic Activity 
Methods  
Preparation of DMF (Dimethylformamide) Suspension 
of Synthesized Compounds: All synthesized compounds 
were dissolved in DMF and used as a suspension in 
physiological saline containing 2 drops of Tween 80 and 
produce a final conc. of 0.2 mg/ml. The standard drug used 
for this study was diazepam. Drugs were administered 
intraperitoneally (IP) in a constant volume of 1 ml/kg, 60 
min before experiments were carried out.  
Animals: Adult male Swiss albino mice weighing 25-35g 
obtained from our animal house. The animals were housed 
at 24±20C with 12: 12 h light and dark cycle. They had free 
access to food and water. The animals were acclimatized for 
a period of 7 days before the study. The experimental 
protocol was approved by the Institutional Animal Ethics 
Committee (IAEC) of Institute of Pharmacy, Bundelkhand 
University, Jhansi (U.P.) India. The animals were used 
according to the CPCSEA guidelines for the use and care of 
experimental animals.  
Experimental Design: On the day of the experiment, the 
animals were divided randomly into control and 
experimental groups (n=6). Group 1 received the vehicle, 
normal saline (10ml/kg) and served as the control group, 
group 2 received the standard drug diazepam (2mg/kg) and 
group 3 to 8 received DMF suspension of synthesized 
compounds (X1 to X6) (Table 2). Drugs were administered 
to the animals 60 minutes prior to the evaluation in acute 
study, for chronic study once daily for a period of 10 days. 
Behavioural evaluation was carried out 60 minutes post 
drug administration on the 10th day. The antianxiety activity 
of the test drug was evaluated using EPM (elevated plus 
maze) test and Bright and dark box test experimental 
models of anxiety. 
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Evaluation of Antianxiety Activity  
Elevated Plus Maze Test  
As per the method described by Kulkarni S.K. et al. [16] the 
wooden maze consisted of two open arms (50cm×10cm) and 
two closed arms of (50cm×10cm×40cm). The arms of same 
type were opposite to each other with a central square of 
10cm.The maze was elevated to a height of 50cm above the 
floor. Each animal was placed in the centre square of plus 
maze, facing one of the open arms. The number of entries 
into and the time spent in open and closed arms in a 5 min 
period was noted.  
Bright and Dark  
The apparatus consisted of an open top wooden box. Two 
distinct chambers, a black chamber (20×30×35cm) painted 
black and illuminated with dimmed red light and a bright 
chamber (30×30×35cm) painted white and brightly 
illuminated with 100 W white light sources, were located 17 
cm above the box. The two chambers were connected 
through a small open doorway (7.5×5cm) situated on the 
floor level at the centre of the partition [17]. 
Behavioural Assessment  
Each animal was tested initially in plus maze and, then, in 
bright and dark arena paradigm in a single setting. In acute 
study 60 min after and in chronic study 60 min after the last 
dose on the 10th day of drug or vehicle administration, each 
animal was placed in the centre square of the plus maze, 
facing one of the open arms. The number of entries into and 
the time spent in open and closed arms and the number of 
rears in each arm in a five-minute period was noted. 
Following the elevated plus maze test, the animal was placed 
at the centre of the brightly lit arena in the light and dark 
box. The number of entries into and the time spent in the 
bright arena, the number of rears in the bright arenas were 
noted. Following each trial, the apparatus were cleaned to 
mask the odour left by the animal in the previous 
experiment. Hand operated counters and stop watches were 
used to score the behaviour of animals.  
Statistical Analysis  
All results were expressed as mean± standard error mean 
(SEM) and analysed by one-way ANOVA. Post-hoc 
comparisons were performed by applying Dunnet’s test. P 
<0.05 was considered statistically significant. 
Results  
Elevated Plus-Maze  
A perusal of Table 4 shows that compared to the standard 
drug, the synthesized compounds X2 and X3 significantly 
increased open arm activity, increasing the duration of time 
spent and number of entries in open arm in EPM test 
compared to control in acute study but in chronic study the 
doses of X2 and X3 produced a greater increase in duration 
of time spent and number of entries in open arm in EPM test 
compared to both control and standard drug diazepam. X2 
had produced better effect than X3 and Diazepam in chronic 
study (Tables 4 & 5).  
Bright and Dark  
Diazepam (1mg/kg) treated mice significantly increased the 
number of entries into the bright arena, the time spent and 
the rears in bright arena. In acute study, both X2 and X3 
significantly increased the number of entries into, time spent 
and rears in bright arena compared to control. X2 and X3 
both had shown significantly increased number of entries 
into, time spent and rears in bright arena when compared to 
control and diazepam in chronic study (Tables 6 & 7).  
Discussion 
The two experimental models of anxiety, elevated plus maze 
and bright and dark arena, are based on the assumption that 
unfamiliar, non-protective and brightly lit environmental 
stress provokes inhibition of normal behaviour. This normal 
behavioural inhibition is further augmented in the presence 
of fear or anxiety like state. In the elevated plus maze, the 
open arms are more fear provoking than the closed arms. 
The ratio of entries, time spent and rearing behaviour in 
open arms to closed arms reflects the safety of closed arms 
with relative fearfulness of open arms [18]. The reduction in 
entry, time spent, total arm entries are the indications of 
high level of fear or anxiety. Anxiolytic drugs increase the 
proportion of entries, time spent in open arms. In the bright 
and dark box paradigm, the brightly lit environment is a 
noxious environment stressor that inhibits the exploratory 
behaviour of rodents. Reduction in the number of entries, 
time spent and rearing behaviour in the bright chamber was 
regarded as markers of anxiety. Rearing reflects an 
exploratory tendency of the animal that can be reduced due 
to a high level of fear [19]. 
In the present study, the compounds X2 and X3 significantly 
increased the duration of time spent and number of entries 
in open arm, time spent in closed arm in EPM test indicating 
anxiolytic activity in both acute and chronic studies. They 
also showed an increase in the time spent and the rears in 
bright arena in the bright and dark arena paradigm. 
Anxiolytic activity of X2 was found to be greater than 
diazepam in chronic study.  
Conclusion 
The derivatives of benzotriazole (X1 to X6) were synthesized 
with the objective to develop better anxiolytic agents with 
maximum percentage of yield and optimal anxiolytic activity. 
The results of the present study suggest that the synthesized 
compounds X2 and X3 have anxiolytic activity better than 
Diazepam. It was observed that three carbon derivatives (n-
propyl or iso-propyl) at N-1 position of imidazolo-thione 
ring improves anxiolytic activity while reduction or 
enhancement in carbon chain or attachment of any aromatic 
substituent, at this place, reduces the anxiolytic property.  
Further investigations with appropriate structural 
modification of title compound may result in therapeutically 
useful products. Further studies are required to elucidate 
the possible mechanism of anxiolytic activity and its 
usefulness in human beings.  
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Table -1 Characterization data of synthesized compounds (5a to 5f) 
Compound (X) R R’ Yield (%) m.p. (0C) Mol. Formula* 
X1 :  (5a) -C2H5 -C6H5 70 130-131 C20H17N7S2 
X2 :  (5b) -CH2CH2CH3 -C6H5 92 104-105 C21H19N7S2 
X3 :  (5c) -CH(CH3)2 -C6H5 80 152-153 C21H19N7S2 
X4 :  (5d) -CH2(CH2)2CH3 -C6H5 85 166-167 C22H21N7S2 
X5 :  (5e) -C(CH3)3 -C6H5 20 148-149 C22H21N7S2 
X6 :  (5f) -C6H5 -C6H5 81 185-186 C24H17N7S2 
 
Table 2:  Experimental design 
Groups Treatment Dose 
I Normal Saline 10ml/kg 
II Diazepam 2mg/Kg 
III Compound X1 2mg/Kg 
IV Compound X2 2mg/Kg 
V Compound X3 2mg/Kg 
VI Compound X4 2mg/Kg 
VII Compound X5 2mg/Kg 
VIII Compound X6 2mg/Kg 
 
Table 3: Spectral data of 2-(substituted)-5-[(N-benzotriazolomethyl)-1,3,4-thiadiazolyl]- imidazole-2-thione 
derivatives 
(a) Interpretation of IR spectra: 
Type Associated Vibration Frequency (in cm-1) 
Imidazole-2-thione ring  >C=S str.  1250, 1560 (interaction between C-S and C-N)  
 C-N str.  1333  
 C=N str.  1670  
Thiadiazole ring  N-N str.  1626.7  
 C=N str.  1670  
 C-S str.  641  
Benzotriazole ring  C-N str.  1271.39  
 C=C str.  1536.15  
 Ar-H str.  3044.19  
 N=N str.  1382  
 
(b)  Interpretation of 1H-NMR spectra: 
Signal position  Relative No. of protons  Inference  
7.68-8.0  9H  Ar-H  
4.98  2H  -CH2 link between benzotriazole and thiadiazole  
6.8  1H  -CH of imidazole 
4.2  2H  >N-CH2- of imidazole  
1.26  3H  >N-CH2-CH3 of imidazole  
 
Table 4:  Acute effect of synthesized compounds on behaviour of mice in elevated plus maze 
Groups 
Number of open arm 
entries 
Number of total arm 
entries 
Time spent in open arm 
(Sec.) 
Time spent in closed arm 
(Sec.) 
Control 3.16±0.47 6.50±0.72 27.00±0.97 182.67±2.33 
Diazepam 
(2mg/kg) 
8.50±0.67* 11.50±1.48* 100.66±1.33* 139.50±3.31* 
X1 (2mg/kg) 5.12±0.54* 7.64±1.44* 84.45±1.22* 122.34±3.30* 
X2 (2mg/kg) 7.33±0.49* 10.66±1.69* 88.50±1.34* 152.50±2.17* 
X3 (2mg/kg) 6.33±0.66* 9.16±0.70* 86.83±0.79* 164.67±2.20* 
X4 (2mg/kg) 5.87±0.62* 8.56±0.85* 85.34±0.83* 134.44±2.10* 
X5 (2mg/kg) 4.56±0.56* 7.12±0.45* 75.07±0.67* 120.22±1.06* 
X6 (2mg/kg) 5.83±0.62* 8.84±0.85* 84.34±0.94* 138.87±2.87* 
Values represented mean±SEM, (n=6), *P<0.05 vs. control  
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Table 5: Chronic effect of synthesized compounds on behaviour of mice in elevated plus maze 
Groups 
Number of open 
arm entries 
Number of total arm 
entries 
Time spent in open 
arm 
Time spent in closed 
arm 
Control 4.39±0.94 8.35±0.65 29.48±1.52 234.92±2.79 
Diazepam 
(2mg/kg) 
8.05±0.62* 11.97±1.36* 88.93±1.07* 197.08±2.32* 
X1 (2mg/kg) 6.04±0.67* 10.34±1.24* 92.78±1.02* 224.45±2.32* 
X2 (2mg/kg) 10.22±0.78** 15.30±0.70** 104.09±1.24** 158.02±2.12** 
X3 (2mg/kg) 9.60±1.06* 15.00±1.33* 102.87±0.80* 170.32±1.39* 
X4 (2mg/kg) 7.88±1.08* 13.56±0.87* 96.56±1.34* 216.45±1.56* 
X5 (2mg/kg) 5.24±0.87* 9.23±0.56* 91.44±0.87* 212.56±1.34* 
X6 (2mg/kg) 7.86±1.08* 13.98±0.98* 103.67±0.76* 209.34±1.67* 
Values represented mean±SEM (n=6), *P<0.05 vs. control, **P<0.05 vs. standard 
Table 6: Acute effect of synthesized compounds on behaviour of mice in bright and dark arena 
Groups 
Number of bright chamber 
entries 
Time spent bright chamber 
(sec) 
Number of rears in bright 
chamber 
Control 1.6±0.61 5.16±0.30 1.09±0.31 
Diazepam 
(2mg/kg) 
2.66 ±0.23* 14.83±0.71* 3.32±0.75* 
X1 (2mg/kg) 1.78±0.22* 12.45±0.65* 2.98±0.42* 
X2 (2mg/kg) 2.74±0.21* 39.33±0.86* 3.18±0.74* 
X3 (2mg/kg) 2.45±0.45* 26.16±0.64* 2.80±0.15* 
X4 (2mg/kg) 2.12±0.02* 14.11±0.45* 2.55±0.34* 
X5 (2mg/kg) 1.33±0.56* 11.45±0.48* 1.67±0.26* 
X6 (2mg/kg) 2.65±0.67* 15.78±0.55* 2.45±0.35* 
Values represented mean±SEM (n=6), *P<0.05 vs. control 
 
Table 7: Chronic effect of synthesized compounds on behaviour of mice in bright and dark arena 
Groups 
Number of bright chamber 
entries 
Time spent bright 
chamber (sec) 
Number of rears in bright 
chamber 
Control 1.31±0.73 5.44±1.02 2.18±0.24 
Diazepam (2mg/kg) 3.12±0.42* 16.23±0.12* 4.62±0.49* 
X1 (2mg/kg) 2.78±0.45* 38.87±0.22* 2.45±0.44* 
X2 (2mg/kg) 5.35±0.27** 45.31±0.94** 6.76±0.35** 
X3 (2mg/kg) 3.76±0.23* 29.71±0.43* 4.94±0.28* 
X4 (2mg/kg) 2.99±0.34* 35.68±0.21* 3.32±0.34* 
X5 (2mg/kg) 1.56±0.56* 30.45±0.32* 3.01±0.56* 
X6 (2mg/kg) 2.87±0.54* 37.34±0.34* 3.56±0.44* 
Values represented mean±SEM (n=6), *P<0.05 vs. control, **P<0.05 vs. standard. 
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